Quick Answer: GLP-1 medications may help some women with PMOS, formerly known as PCOS, especially when insulin resistance, higher weight, prediabetes, type 2 diabetes, androgen excess, or cardiometabolic risk are part of the picture
Data on whether tirzepatide lowers cardiovascular outcomes is not expected until 2025
Some patients report better gastrointestinal tolerance with oral formulations, though this varies individually
Women following a structured semaglutide diet plan that prioritizes fatty fish, eggs, and fortified foods will naturally address both deficiencies
These results have not been replicated in human clinical trials, so it is unclear whether these effects translate to human patients
For anyone weighing the benefits against these risks, comparing glutathione IV to oral supplementation can provide additional perspective